Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI...
11 2월 2019 - 10:00PM
PRESS RELEASE
Lund Sweden, February 11 2019
- Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that their
partner NeoTX enters a clinical collaboration with AstraZeneca
Group Plc (NYSE: AZN) global biologics research and development
arm, MedImmune, to support Phase 1b/2 studies investigating ANYARA
in combination with AstraZeneca's IMFINZI®.
IMFINZI® (durvalumab)
is a human monoclonal antibody that blocks the immune checkpoint
protein programmed death-ligand (PD-L1). Under terms of the
agreement, NeoTX and AstraZeneca will collaborate on a
non-exclusive basis to evaluate the combination of the two drugs in
solid tumors. NeoTX will sponsor the study, while AstraZeneca will
supply durvalumab. Up to 195 patients are planned to be enrolled in
this multicenter, open-label study, which is planned to start
during 2019.
"We are very pleased with NeoTX's progress in the
ANYARA project. The collaboration with AstraZeneca validates the
project and is an important step towards start of the clinical
study" says Helén Tuvesson, CEO, Active Biotech AB.
See also www.neotx.com for NeoTX's communication related to this
information.
ABOUT ANYARA
ANYARA (Naptumumab, Naptumomab estafenatox,) is a
tumor targeting immunotherapy that enhances the ability of the
immune system to recognize and kill the tumor. ANYARA induces the
activation and expansion of specific T cells outside of the tumor
microenvironment and redirect the T cells to attack the tumor
cells. Preclinical data demonstrate that ANYARA has synergistic
effect with checkpoint inhibitors in various tumor models.
Active Biotech has an agreement with NeoTX
Therapeutics Ltd since October 2016 for the global development and
commercialization of ANYARA for the treatment of cancer.
About NeoTX
NeoTX Ltd. is a clinical-stage biopharmaceutical company dedicated
to developing promising therapeutic candidates in the field of
immuno-oncology. The Company in-licenses novel compounds, primarily
from academic institutions and biotech companies.
Lund February 11 2019
Helèn Tuvesson
President & CEO
For further information, please
contact:
Helén Tuvesson, CEO
Tel +46 46 19 21 56
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ)
(NASDAQ Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties in development for neurodegenerative diseases. ANYARA,
an immunotherapy, in development for cancer indications in
partnership with NeoTX Therapeutics Ltd. Furthermore, commercial
activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit www.activebiotech.com for more
information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information
that Active Biotech AB is obliged to make public pursuant to the EU
Market Abuse Regulation. This information was submitted for
publication, through the agency of the contact person set out
above, at 14.00 p.m. CET
on February 11, 2019.
AB's partner NeoTX enters clin.
collab. with AstraZeneca for ANYARA
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024